» Articles » PMID: 38331871

Beyond the Barrier: the Immune-inspired Pathways of Tumor Extravasation

Overview
Publisher Biomed Central
Date 2024 Feb 8
PMID 38331871
Authors
Affiliations
Soon will be listed here.
Abstract

Extravasation is a fundamental step in the metastatic journey, where cancer cells exit the bloodstream and breach the endothelial cell barrier to infiltrate target tissues. The tactics cancer cells employ are sophisticated, closely reflecting those used by the immune system for tissue surveillance. Remarkably, tumor cells have been observed to form distinct associations or clusters with immune cells where neutrophils stand out as particularly crucial partners. These interactions are not accidental; they are critical for cancer cells to exploit the immune functions of neutrophils and successfully extravasate. In another strategy, tumor cells mimic the behavior and characteristics of immune cells. They release a suite of inflammatory mediators, which under normal circumstances, guide the processes of endothelium reshaping and facilitate the entry and movement of immune cells within tissues. In this review, we offer a new perspective on the tactics employed by cancer cells to extravasate and infiltrate target tissues. We delve into the myriad mechanisms that tumor cells borrow, adapt, and refine from the immune playbook. Video Abstract.

Citing Articles

Neutrophils in cancer: from biology to therapy.

Koenderman L, Vrisekoop N Cell Mol Immunol. 2024; 22(1):4-23.

PMID: 39653768 PMC: 11686117. DOI: 10.1038/s41423-024-01244-9.


Extracellular nicotinamide phosphoribosyltransferase (eNAMPT) drives abnormal pericyte-rich vasculature in triple-negative breast cancer.

Moro M, Balestrero F, Colombo G, Torretta S, Clemente N, Ciccone V Angiogenesis. 2024; 28(1):4.

PMID: 39636369 DOI: 10.1007/s10456-024-09956-2.


Understanding the role of TNFR2 signaling in the tumor microenvironment of breast cancer.

Mussa A, Ismail N, Hamid M, Al-Hatamleh M, Bragoli A, Hajissa K J Exp Clin Cancer Res. 2024; 43(1):312.

PMID: 39609700 PMC: 11603874. DOI: 10.1186/s13046-024-03218-1.


Interleukin-1 Receptor-Associated Kinase 1 in Cancer Metastasis and Therapeutic Resistance: Mechanistic Insights and Translational Advances.

Najjar M, Khan M, Zhuang C, Chandra A, Lo H Cells. 2024; 13(20.

PMID: 39451208 PMC: 11506742. DOI: 10.3390/cells13201690.


Assessing the metastatic potential of circulating tumor cells using an organ-on-chip model.

Schmid K, Zeinali S, Moser S, Dubey C, Schneider S, Deng H Front Bioeng Biotechnol. 2024; 12:1457884.

PMID: 39439549 PMC: 11493642. DOI: 10.3389/fbioe.2024.1457884.


References
1.
Ramasamy S, Saez B, Mukhopadhyay S, Ding D, Ahmed A, Chen X . Tle1 tumor suppressor negatively regulates inflammation in vivo and modulates NF-κB inflammatory pathway. Proc Natl Acad Sci U S A. 2016; 113(7):1871-6. PMC: 4763742. DOI: 10.1073/pnas.1511380113. View

2.
Salminen A, Allahyari Z, Gholizadeh S, McCloskey M, Ajalik R, Cottle R . Studies of Transendothelial Migration for Biological and Drug Discovery. Front Med Technol. 2022; 2:600616. PMC: 8757899. DOI: 10.3389/fmedt.2020.600616. View

3.
Le Guelte A, Galan-Moya E, Dwyer J, Treps L, Kettler G, Hebda J . Semaphorin 3A elevates endothelial cell permeability through PP2A inactivation. J Cell Sci. 2012; 125(Pt 17):4137-46. DOI: 10.1242/jcs.108282. View

4.
Vismara M, Reduzzi C, Daidone M, Cappelletti V . Circulating Tumor Cells (CTCs) Heterogeneity in Metastatic Breast Cancer: Different Approaches for Different Needs. Adv Exp Med Biol. 2020; 1220:81-91. DOI: 10.1007/978-3-030-35805-1_6. View

5.
Koenen R, Pruessmeyer J, Soehnlein O, Fraemohs L, Zernecke A, Schwarz N . Regulated release and functional modulation of junctional adhesion molecule A by disintegrin metalloproteinases. Blood. 2009; 113(19):4799-809. DOI: 10.1182/blood-2008-04-152330. View